Format

Send to

Choose Destination
Schizophr Res. 2017 May;183:143-150. doi: 10.1016/j.schres.2016.11.026. Epub 2016 Nov 25.

A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT).

Author information

1
Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow, United Kingdom. Electronic address: andrew.gumley@glasgow.ac.uk.
2
Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow, United Kingdom; Institute of Psychology, Health and Society, University of Liverpool, United Kingdom.
3
Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, United Kingdom.
4
Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, United Kingdom.
5
Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow, United Kingdom.
6
NHS Greater Glasgow & Clyde, United Kingdom.

Abstract

BACKGROUND:

Depression is one of the major contributors to poorer quality of life amongst individuals with psychosis and schizophrenia. The study was designed as a Pilot Trial to determine the parameters of a larger, definitive pragmatic multi-centre randomised controlled trial of Acceptance and Commitment Therapy for depression after psychosis (ACTdp) for individuals with a diagnosis of schizophrenia who also meet diagnostic criteria for major depression.

METHODS:

Participants were required to meet criteria for schizophrenia and major depression. Blinded follow-ups were undertaken at 5-months (end of treatment) and at 10-months (5-months posttreatment). Primary outcomes were depression as measured by the Calgary Depression Scale for Schizophrenia (CDSS) and the Beck Depression Inventory (BDI).

RESULTS:

A total of 29 participants were randomised to ACTdp + Standard Care (SC) (n=15) or SC alone (n=14). We did not observe significant differences between groups on the CDSS total score at 5-months (Coeff=-1.43, 95%CI -5.17, 2.32, p=0.45) or at 10-months (Coeff=1.8, 95%CI -2.10, 5.69, p=0.36). In terms of BDI, we noted a statistically significant effect in favour of ACTdp+SC at 5-months (Coeff=-8.38, 95%CI -15.49, -1.27, p=0.02) but not at 10-months (Coeff=-4.85, 95%CI -12.10, 2.39, p=0.18). We also observed significant effects on psychological flexibility at 5-months (Coeff=-8.83, 95%CI -14.94, -2.71, p<0.01) but not 10-months (Coeff=-4.92, 95%CI -11.09, 1.25, p=0.11).

IMPLICATIONS:

In this first RCT of a psychological therapy with depression as the primary outcome, ACT is a promising intervention for depression in the context of psychosis. A further large-scale definitive randomised controlled trial is required to determine effectiveness.

TRIAL REGISTRATION:

ISRCTN: 33306437.

KEYWORDS:

Acceptance and Commitment Therapy; Depression; Pilot; Randomised controlled trial; Schizophrenia

PMID:
27894822
DOI:
10.1016/j.schres.2016.11.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center